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Abstract. Background/Aim: Cisplatin-based radical
chemoradiotherapy (CRT) is utilised in oesophagogastric (OG)
cancer but the toxicity profile of cisplatin limits its use. This
study aimed to evaluate the clinical characteristics and
outcomes of patients treated with either cisplatin or carboplatin
based CRT at our institution. Materials and Methods: This is a
retrospective analysis of patients with localised OG cancer
undergoing CRT with cisplatin/fluoropyrimidine (CX/F) or
carboplatin/fluoropyrimidine (CarboX/F) between January
2001 and December 2014. Results: A total of 91 eligible
patients were included. Median age was 65 years (IQR=57-75)
for CX/F and 77 years (IQR=69-80) for CarboX/F.
Adenocarcinoma histology and Charlson comorbidity index
were higher in the CarboX/F group. Endoscopic complete
response (CR) was achieved in 64% of CX/F group and 48% of
CarboX/F group (p=0.19). The median PFS for CX/F was 31.0
months (95%CI=18.2-NE) vs. 18.7 months for CarboX/F
(95%CI=13.5-30.4; HR=1.49, p=0.21). Conclusion: Despite
significant differences in baseline clinical characteristics,
patients treated with carboplatin CRT demonstrated no
significant difference in PFS or endoscopic CR rate, compared
to those treated with cisplatin. 
Cancers of the oesophagus or oesophagogastric junction
(OGJ) remain an important cause of cancer-related morbidity
and mortality worldwide (1) with a significant proportion of
patients presenting with locally advanced or advanced
disease. Globally, squamous cell carcinoma represents the
predominant histological type of oesophageal cancer, but
there has been a rapid rise in the incidence of oesophageal
adenocarcinoma in western populations over recent years (2).
In the UK, rates of oesophageal cancer incidence and
mortality are near comparable with 9,000 new cases
diagnosed each year and 7,900 deaths each year (3). 
The application of multi-modality therapy utilising either
neoadjuvant chemotherapy or chemoradiotherapy (CRT)
prior to surgical resection has led to increased survival and
locoregional control rates for both squamous cell carcinoma
and adenocarcinoma (4, 5). In selected patients with
localised disease who are deemed unsuitable for surgery,
CRT can be utilised as an alternative radical treatment
option. The combination of cisplatin and fluoropyrimidine
is a standard choice for the chemotherapy component of
CRT. Due to its toxicity profile and hydration requirements,
cisplatin is not suitable for many patients with renal
impairment, hearing impairment, neuropathy or significant
cardiac dysfunction. In these circumstances, carboplatin is
considered as an alternative platinum compound but there
remains a lack of prospective randomised data to support
this substitution in oesophagogastric (OG) cancer.
Comparative data do, however, exist for this substitution in
other cancers which utilise platinum-containing regimens,
such as non-small cell lung cancer (NSCLC) and ovarian
cancer. 
A meta-analysis of randomised controlled trials
comparing cisplatin-based regimens to carboplatin-based
regimens in advanced NSCLC demonstrated a higher
overall response rate to cisplatin, but no survival
advantage over carboplatin (6). Toxicity profiles differed
between the groups with higher rates of nausea, vomiting
and nephrotoxicity with cisplatin compared to higher rates
of thrombocytopenia with carboplatin. Furthermore,
prospective data from a randomised phase 3 trial
comparing chemotherapy regimens containing carboplatin
AUC6 versus two different doses of cisplatin (80 mg/m2
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and 50 mg/m2) failed to show any differences in survival
or patient reported outcomes between the carboplatin and
cisplatin 80 mg/m2 groups (7). Therefore, these two
platinum compounds are widely used interchangeably in
NSCLC and treatment choice is usually dictated by
tolerability and the toxicity profiles of each drug.
Similarly, randomised phase 3 non-inferiority studies in
ovarian cancer (8, 9) have shown no survival advantage with
cisplatin over carboplatin but improved tolerability, better
quality of life and easier administration with carboplatin-
containing regimens, thereby leading to the preferred use of
carboplatin in this disease. 
In this retrospective study we sought to evaluate the clinical
characteristics and outcomes of patients with localised OG
cancer undergoing radical CRT with either carboplatin or
cisplatin-based chemotherapy at our institution. 
Materials and Methods
Methods. The Royal Marsden Hospital Electronic Patient Record
(EPR) system was searched for patients with OG (oesophagus,
oesophagogastric junction (OGJ) or gastric) cancer consecutively
treated at the institution over a fourteen-year period between
January 2001 and December 2014. Patients with localised OG
cancer who received radical chemoradiotherapy utilising cisplatin
and fluoropyrimidine or carboplatin and fluoropyrimidine were
identified. Patients who received neoadjuvant triplet chemotherapy
including epirubicin were excluded from this analysis. All patients
required a minimum of three years follow up. A data collection tool
was designed and all relevant clinical data including patient
demographics, disease characteristics, chemotherapy drugs,
radiation doses and outcomes were retrieved from EPR by the
authors. The Charlson comorbidity index (CCI) (10), which predicts
the 1 year mortality for patients with a range of comorbidities, was
calculated for all eligible patients at baseline. For those patients
treated with carboplatin in place of cisplatin, the reason for platinum
substitution was recorded. Data on frequency of cytopenias during
treatment and deterioration in creatinine was collected for each
group as a surrogate marker of toxicity. Study approval was sought
and obtained from the hospital trust’s Committee for Clinical
Research. 
Statistical analysis. Participant and disease characteristics were
analysed using descriptive statistics; for categorical variables,
numbers with percentages plus means and standard deviations were
presented and for continuous variables, medians along with lower
and upper quartiles were presented. Progression-free survival (PFS)
was calculated as time from start of chemotherapy treatment to date
of progression or death from any cause. Overall survival (OS) was
calculated for all patients as time from start of chemotherapy to
death from any cause or last follow up. Patients without an event
were censored at date of last follow up. Survival estimates and 95%
confidence intervals were determined using the Kaplan–Meier
method whilst the Cox regression method was used to describe and
compare survival hazard rates between the two chemotherapy
groups and to adjust for the effect of covariates. Stata v13.1 was
used for the analysis. 
Results
Patient and disease characteristics. A total of 940 patients
with a diagnosis of OG cancer who received some form of
systemic platinum chemotherapy for any indication during
the study time period were screened, of which 91 patients
met the eligibility criteria. Of these, 42 patients received
cisplatin/fluoropyrimidine (CX/F) CRT and 49 received
carboplatin/fluoropyrimidine (CarboX/F) CRT. All patients
received a radical dose of concomitant radiotherapy, most
frequently 54 Gy in 30 fractions (range=50-59 Gy in 25-31
fractions). The median age of patients in the CX/F group was
65 years (IQR=57-75) and in the CarboX/F group was 77
years (IQR=69-80). The majority of patients in both groups
had an ECOG performance status (PS) of ≥1 at the start of
treatment (81% CX/F and 96% CarboX/F). There was a
higher proportion of adenocarcinoma histology in the
CarboX/F group compared to the CX/F group (59% vs. 29%)
and the calculated Charlson comorbidity index (CCI) was
also higher in the CarboX/F group (CCI>5=57% vs. 17%).
Baseline demographic, clinical and pathological
characteristics are summarised in Table I. The most frequent
reasons for implementing platinum substitution with
carboplatin were age (33%), hearing impairment (18%),
renal impairment (16%) and other comorbidities (16%). 
Toxicity. Six patients (14%) in the CX/F group and six
patients (12%) in the CarboX/F group experienced an
episode of neutropenia during treatment. Eight patients
(19%) in the CX/F group experienced an episode of
thrombocytopenia compared to 22 (45%) in the CarboX/F
group (p=0.009). Nine patients (21%) in the CX/F group
required a blood transfusion during the treatment period
compared to 22 (45%) in the CarboX/F group. Two patients
in the CX/F group and one patient in the CarboX/F group
experienced deterioration in creatinine during treatment.
Eight patients (19%) in the CX/F group required a dose
modification of chemotherapy during treatment compared to
19 patients (39%) in the CarboX/F group. Of these patients,
three patients in the CX/F group required a dose
modification of cisplatin and 11 patients in the CarboX/F
group required a dose modification of carboplatin (p=0.011).  
Treatment outcomes
Response. Responses to CRT as assessed by 12-week post-
treatment CT imaging and endoscopic biopsy are outlined in
Table II. The complete response (CR) at endoscopic biopsy
rate was 64% for the CX/F group and 48% for the CarboX/F
group (p=0.19). 
Survival. The median PFS for the CX/F group was 31.0
months (95%CI=18.2-NE) and for the CarboX/F group was
18.7 months (95%CI=13.5-30.4); adjusting for age,
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comorbidity and pathology: HR=1.49, p=0.21). Median OS
for the CX/F group was not reached (95%CI=63.9-NE) and
for the CarboX/F group was 36.3 months (95%CI=24.1-
68.5); adjusting for age, comorbidity and pathology: HR
1.92, p=0.09) (Figures 1 and 2). The 3-year PFS rate for the
CX/F group was 48% and for the CarboX/F group was 28%.
The 5-year OS rate for the CX/F group was 70% and for the
CarboX/F group was 38%. Sixty-one patients (45%) had
died at last follow up, 72 patients (53%) were alive and 1
patient was lost to follow up. Of the patients who were still
alive, 5 were receiving ongoing treatment, 19 had evidence
of progressive disease with no further treatment options
available and 48 had no evidence of active disease. The
median duration of follow up was 53.8 months. 
Subgroup analysis. Due to the large discrepancies in age and
comorbidity index between the two groups, a further
subgroup analysis was performed by comparing those
patients who received carboplatin substitution primarily due
to isolated hearing or renal impairment (n=19). However, the
clinical characteristics of this subgroup did not significantly
differ from the overall CarboX/F population. Within this
CarboX/F subgroup, the median age at diagnosis was 75
years (IQR=66-79), proportion of patients with a CCI>5 was
53% and the proportion of adenocarcinoma histology was
53% (Table III). The median PFS for this group was 22.8
months (95%CI=16.2-NE; HR=0.75, p=0.12) (Figure 3). 
Discussion
The toxicity profile of cisplatin limits its utility in patients
with renal impairment, hearing impairment, cardiac
dysfunction & neuropathy amongst other comorbidities. In
this situation, cisplatin is commonly substituted with
carboplatin which has a preferred toxicity profile in this
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Table I. Baseline demographic, clinical and pathological characteristics.
                                                                CX/F         CarboX/F     p-Value
                                                               (n=42)           (n=49)
                                                              No. (%)         No. (%)             
Median age at diagnosis (IQR)           65 (57-75)    77 (69-80)    <0.001
Gender                                                                                                 
   Male                                                   24(57)         32 (65)              
   Female                                              18 (43)         17 (35)            0.52
PS at start                                                                                            
   0                                                           8 (19)           2 (4)                
   1                                                        30 (71)         39 (81)              
   2                                                           4 (10)           6 (13)              
   3                                                           0 (0)             1 (2)              0.12
Charlson Co-morbidity Index (CCI)         
   2-3                                                     12 (29)           5 (10)              
   4-5                                                     23 (55)         10 (33)              
   >5                                                        7 (17)         16 (57)         <0.001
Primary site                                                                                         
   Oesophagus                                       34 (81)         32 (65)              
   OGJ type I                                          7 (17)           7 (14)              
   OGJ type II                                         1 (2)             7 (14)              
   OGJ type III                                        0 (0)             2 (4)                
   Stomach                                              0 (0)             1 (2)              0.11
Histology                                                                                             
   Adenocarcinoma                               12 (29)         29 (59)              
   Squamous                                         30 (71)         20 (41)            0.003
RT dose                                                                                              
   54Gy                                                 39 (93)         48 (98)              
   Other                                                   3 (7)             1 (2)              0.33
Received neoadjuvant chemotherapy   40 (95)         46 (94)              
Table II. Response to CRT.
                                                                CX/F         CarboX/F     p-Value
                                                              No. (%)         No. (%)
Response post CRT                                                                          
   CR (endoscopic biopsy)                   25 (64)         23 (48)            0.19 
   PR                                                       4 (10)           4 (8)                
   SD                                                       5 (13)           8 (17)              
   PD                                                       3 (8)             5 (10)              
Residual disease                                     2 (5)             8 (17)              
Total                                                      39 (100)       48 (100)          0.42
Table III. Baseline characteristics of CarboX/F group with
hearing/renal impairment as primary reason for platinum substitution.
                                                               CX/F         CarboX/F    p-Value
                                                               (n=42)           (renal/
                                                              No. (%)     hearing imp)
                                                                                     (n=19)
                                                                                    No. (%)
Median age at diagnosis (IQR)           65 (57-75)    75 (66-79)      0.02
Gender                                                                                                 
   Male                                                  24 (57)         11 (58)              
   Female                                              18 (43)           8 (42)            0.956
PS at start                                                                                            
   0                                                           8 (19)           1 (5)                
   1                                                        30 (71)         17 (89)              
   2                                                           4 (10)           1 (5)              0.40
Co-morbidity                                                                                      
   2-3                                                     12 (29)           3 (16)              
   4-5                                                     23 (55)           6 (31)              
   >5                                                        7 (17)         10 (53)            0.02
Histology                                                                                             
   Adenocarcinoma                               12 (29)         10 (53)              
   Squamous                                         30 (71)           9 (47)            0.9
clinical setting. Although survival outcomes with platinum
substitution are comparable in other tumour types, this has
not been prospectively analysed in OG cancer and there is
little published data. To our knowledge, we present the first
data to describe the clinical characteristics and comparative
outcomes for patients with localised OG cancer undergoing
radical CRT with either CarboX/F or CX/F.
Within our institution, patients with locally advanced OG
cancer who underwent radical CRT with carboplatin
substitution were significantly older than those who received
cisplatin (median age 77 years vs. 65 years). In addition,
patients who received carboplatin had higher Charlson
comorbidity index scores as well as a higher proportion with
adenocarcinoma histology. The differences in patient
characteristics were more significant than we had anticipated
but can be understood as the presence of renal impairment,
hearing impairment & cardiac dysfunction will be associated
with an older, frailer patient population.  This group
represents a clinically challenging population of patients who
are often deemed unsuitable for cisplatin. In addition, this
patient group is often excluded from clinical trials (involving
cisplatin) due to stringent eligibility criteria meaning there is
an absence of prospective data on which to base treatment
recommendations. 
As the majority of cancers in the developed world are
diagnosed in patients aged 70 years and over, it is now
recognised that cancer is predominantly a disease of older
people. However, outcomes remain poorer in these patients
and there is a disparity in treatment options compared to
younger patients. In recognition of this, the European
ANTICANCER RESEARCH 38: 5943-5949 (2018)
5946
Figure 1. Progression-free survival (PFS) for CX/F versus CarboX/F.
Organisation for Research and Treatment of Cancer
(EORTC) established the Cancer in the Elderly Taskforce
with the aim of improving research and clinical trial access
for older patients in order to determine the optimal standards
of care in the geriatric population. This recognition will help
to develop prospective data to guide treatment decisions in
older patients who are often excluded from clinical trials due
to comorbidity or frailty. An integrated oncogeriatric
approach in the assessment and optimisation of older patients
with comorbidity has emerged as a top priority for the
geriatric oncology community. Thus, the incorporation of
comorbidity and functional assessments (such as the timed
up and go test) in guiding management decisions and
determining the best treatment options on an individual
patient basis is becoming more commonplace (11). 
In spite of the differences in the baseline clinical
characteristics of the two groups in our cohort, endoscopic
CR rates following completion of CRT showed no significant
difference between the CX/F and CarboX/F groups despite
a higher proportion of adenocarcinoma histology in the
carboplatin group. In addition, there was no significant
difference in PFS between the two groups after adjusting for
age, comorbidity and histology. Although OS appears to be
longer in the cisplatin group, this must be interpreted with
caution given the differing patient characteristics at baseline. 
Recent studies have shown that the utilisation of
alternative non-cisplatin based chemotherapy regimens can
produce favourable and comparable outcomes to cisplatin-
based regimens. The CROSS study assessed carboplatin in
combination with low dose paclitaxel in a neoadjuvant CRT
approach for operable oesophageal and OGJ tumours (5).
Pathological CR and survival rates were comparable to trials
using CX regimes. The PRODIGE5/ACCORD17 study used
FOLFOX (fluorouracil, leucovorin and oxaliplatin) in
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Figure 2. Overall survival (OS) for CX/F versus CarboX/F.
definitive CRT for oesophageal cancer with comparable
survival outcomes but reduced toxicity and increased ease of
administration compared to CX (12). In addition, platinum
substitution of cisplatin with carboplatin, specifically, has
also recently been written into trial protocols. In SCOPE- 1
(13), cisplatin was substituted with carboplatin if GFR was
below 40 ml/min and in the currently recruiting SCOPE-2
study [NCT02741856], platinum substitution is allowed for
hearing impairment or neuropathy. In allowing cisplatin
substitution within these protocols, these studies allow an
increased population of trial participants and the results will
be more clinically relevant to real-life practice. 
Conclusion
Our findings showed that, despite treating an older population
with increased comorbidity, outcomes of patients with localised
OG cancer treated at our institution with carboplatin
substitution are not significantly worse than for those patients
treated with cisplatin. These findings lend support to the
selective use of carboplatin substitution in localised OG cancer. 
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